Thrombolysis After Dabigatran Reversal for Acute Ischemic Stroke: A National Registry-Based Study and Meta-Analysis.

Aikaterini TheodorouKonstantinos MelanisEleni BakolaMaria ChondrogianniArgyro KiamiliPanagiotis PlomaritisKlearchos PsychogiosApostolos SafourisOdysseas KargiotisEvangelos NtaisMaria-Ioanna StefanouLina Palaiodimou Amrou Sarraj David Julian Seiffge Sotirios Giannopoulos Georgios K Tsivgoulis

Published in: Neurology (2024)

IVT for AIS after dabigatran reversal with idarucizumab seems to be safe and effective in observational studies with limited number of patients. Randomized-controlled clinical trials are warranted to provide robust evidence on the safety and efficacy of IVT in this specific AIS subgroup.

Keyphrases

acute ischemic stroke
clinical trial
end stage renal disease
atrial fibrillation
phase iii
ejection fraction
newly diagnosed
open label
double blind
prognostic factors
pulmonary embolism
peritoneal dialysis
phase ii
quality improvement
randomized controlled trial
patient reported outcomes
study protocol